Benefits and harms of osteoporosis medications in patients with CKD unclear
KEY POINT
The safety and beneficial effects of osteoporosis medications on bone mineral density (BMD) and fracture risk in patients with chronic kidney disease (CKD) are unclear, according to results of a systematic review and meta-analysis published in the Annals of Internal Medicine.
SOURCES
Wilson LM, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med. 2017;166(9):649–58.
